Document:

THE SECURITIES REPRESENTED BY THIS INSTRUMENT
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS
OF ANY STATE AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF EXCEPT WHILE A REGISTRATION STATEMENT RELATING THERETO IS
IN EFFECT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR SUCH
LAWS. EACH PURCHASER OF THE SECURITIES REPRESENTED BY THIS INSTRUMENT IS NOTIFIED THAT THE SELLER MAY BE RELYING ON THE EXEMPTION
FROM SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER. ANY TRANSFEREE OF THE SECURITIES REPRESENTED BY THIS INSTRUMENT
BY ITS ACCEPTANCE HEREOF (1) REPRESENTS THAT IT IS A “QUALIFIED INSTITUTIONAL BUYER” (AS DEFINED IN RULE 144A UNDER
THE SECURITIES ACT), (2) AGREES THAT IT WILL NOT OFFER, SELL OR OTHERWISE TRANSFER THE SECURITIES REPRESENTED BY THIS INSTRUMENT
EXCEPT (A) PURSUANT TO A REGISTRATION STATEMENT WHICH IS THEN EFFECTIVE UNDER THE SECURITIES ACT, (B) FOR SO LONG AS THE SECURITIES
REPRESENTED BY THIS INSTRUMENT ARE ELIGIBLE FOR RESALE PURSUANT TO RULE 144A, TO A PERSON IT REASONABLY BELIEVES IS A “QUALIFIED
INSTITUTIONAL BUYER” AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT THAT PURCHASES FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT
OF A QUALIFIED INSTITUTIONAL BUYER TO WHOM NOTICE IS GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, (C) TO THE
ISSUER OR (D) PURSUANT TO ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND (3) AGREES
THAT IT WILL GIVE TO EACH PERSON TO WHOM THE SECURITIES REPRESENTED BY THIS INSTRUMENT ARE TRANSFERRED A NOTICE SUBSTANTIALLY TO
THE EFFECT OF THIS LEGEND.

 

CITIGROUP INC.

6.675% Subordinated Notes due September
13, 2043

 

	REGISTERED	 	REGISTERED
	 	 	 
	No. R-0001	 	$1,000,000,000

 

CITIGROUP INC., a Delaware corporation
(the “Company”, which term includes any successor Person under the Indenture), for value received, hereby promises
to pay to the Federal Deposit Insurance Corporation, or registered assigns, the principal sum of $1,000,000,000 on September 13,
2043 and to pay interest thereon from and including September 9, 2013 or from the most recent Interest Payment Date (as defined
herein) to which interest has been paid or duly provided for, semi-annually, on March 13 and September 13 of each year, commencing
March 13, 2014, at the rate of 6.675% per annum, until the principal hereof is paid or made available for payment (each such payment
date, an “Interest Payment Date”). The subordinated notes may be redeemed in whole, but not in part, at any time if
changes involving United States taxation occur which could require Citigroup to pay additional amounts.

 

    	 

    	 

    

 

The interest so payable, and punctually
paid or duly provided for, on any Interest Payment Date will, as provided in the Indenture, be paid pursuant to the instructions
of the Person in whose name this Subordinated Note is registered at the close of business on the Record Date for such interest,
which shall be the Business Day immediately preceding such Interest Payment Date.

 

Any such interest not so punctually paid
or duly provided for will forthwith cease to be payable to the holder on such Record Date and may either be paid pursuant to the
instructions of the Person in whose name this Subordinated Note is registered at the close of business on a subsequent Record Date,
such subsequent Record Date to be not less than five days prior to the date of payment of such defaulted interest, notice whereof
shall be given to holders of Subordinated Notes of this series not less than 15 days prior to such subsequent Record Date.

 

Interest hereon will be calculated on the
basis of a 360-day year comprised of twelve 30-day months or, in the case of an incomplete month, the number of days elapsed. In
the event the subordinated notes do not continue to remain in book-entry only form, Citigroup shall have the right to select record
dates, which shall be more than 14 days but less than 60 days prior to an interest payment date.

 

If an Interest Payment Date falls on a day
that is not a Business Day, such Interest Payment Date will be the next succeeding Business Day, and no further interest will accrue
in respect of such postponement. If the Maturity of the Subordinated Notes falls on a day that is not a Business Day, the payment
due on Maturity will be postponed to the next succeeding Business Day, and no further interest will accrue in respect of such postponement.
If a date for payment of interest or principal on the Subordinated Notes falls on a day that is not a business day in the place
of payment, such payment will be made on the next succeeding business day in such place of payment as if made on the date the payment
was due.

 

For these purposes, “Business Day”
means any day on which commercial banks settle payments and are open for general business in The City of New York.

 

Payment of the principal of and interest
on this Subordinated Note will be made at the office or agency of the Trustee maintained for that purpose in The City of New York.

 

Reference is hereby made to the further
provisions of this Subordinated Note set forth on the reverse hereof, which further provisions shall for all purposes have the
same effect as if set forth at this place.

 

Unless the certificate of authentication
hereon has been executed by the Trustee or by an authenticating agent on behalf of the Trustee by manual signature, this Subordinated
Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

    	2

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed under its corporate seal.

 

Dated: September 9, 2013

 

	 	CITIGROUP INC.
	 	 	 
	 	By:	
	 	 	Name:	
	 	 	Title:	

  

ATTEST:

 

	By:		 
	Name: 	 
	Title:  	 

 

[CORPORATE SEAL]

 

    	3

    	 

    

 

This is one of the Notes of the series
issued under the within-mentioned Indenture.

 

Dated: September 9, 2013

 

	 	THE BANK OF NEW YORK MELLON,
	 	as Trustee
	 	 	 
	 	By:	
	 	 	Name:
	 	 	Title:
	 	 	 
	 	-or-
	 	 
	 	CITIBANK, N.A.,
	 	as Authenticating Agent
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	4

    	 

    

 

This Subordinated Note is one of a duly
authorized issue of Securities of the Company (the “Subordinated Notes”), issued and to be issued in one or more series
under the Indenture, dated as of April 12, 2001, as supplemented August 2, 2004 (as so supplemented, the “Indenture”),
between the Company and The Bank of New York Mellon (successor to J.P. Morgan Trust Company, N.A. and Bank One Trust Company, N.A.),
as Trustee (the “Trustee”, which term includes any successor trustee under the Indenture), to which Indenture and all
indentures supplemental thereto reference is hereby made for a statement of the respective rights, limitations of rights, duties
and immunities thereunder of the Company, the Trustee and the holders of the Subordinated Notes and of the terms upon which the
Subordinated Notes are, and are to be, authenticated and delivered. This Subordinated Note is one of the series designated on the
face hereof, initially limited in aggregate principal to $1,000,000,000.

 

The Company covenants and agrees that the
indebtedness evidenced by the Subordinated Notes is subordinate and junior in right of payment to all Senior Indebtedness (as defined
in the Indenture as supplemented by the Board Resolutions of the Company establishing the terms of the Subordinated Notes, the
“Resolutions”) to the extent provided in the Indenture, and each holder of Subordinated Notes, by his or her acceptance
thereof, likewise covenants and agrees to the subordination provided in the Indenture (including Article Fourteen thereof) and
shall be bound by the provisions thereof.

 

In the event that the Company shall default
in the payment of any principal of (or premium, if any) or interest on any Senior Indebtedness when the same becomes due and payable
after any applicable grace period, whether at maturity or at a date fixed for prepayment or by declaration or otherwise, then,
unless and until such default shall have been cured or waived or shall have ceased to exist, no direct or indirect payment (in
cash, property, securities, by set-off or otherwise) shall be made or agreed to be made on account of the principal of, or premium,
if any, or interest on the indebtedness evidenced by the Subordinated Notes, or in respect of any redemption, retirement or other
acquisition of any of the Subordinated Notes, except that holders of Subordinated Notes may receive and retain (x) securities of
the Company or any other corporation provided for by a plan of reorganization or readjustment the payment of which is subordinate,
at least to the extent provided in these subordination provisions with respect to the indebtedness evidenced by the Subordinated
Notes, to the payment of all Senior Indebtedness at the time outstanding and to any securities issued in respect thereof under
any such plan of reorganization or readjustment and (y) payments made from a defeasance trust created pursuant to Article Eleven
of the Indenture.

 

In the event of:

 

(i) any insolvency, bankruptcy, receivership,
liquidation, reorganization, readjustment, composition or other similar proceeding relating to the Company, its creditors or its
property,

 

    	5

    	 

    

 

(ii) any proceeding for liquidation, dissolution
or other winding up of the Company, voluntary or involuntary, whether or not involving insolvency or bankruptcy proceedings,

 

(iii) any assignment by the Company
for the benefit of creditors, or

 

(iv) any other marshalling of
the assets of the Company,

 

all Senior Indebtedness (including any interest thereon accruing
after the commencement of any such proceedings) shall first be paid in full before any payment or distribution, whether in cash,
securities or other property, shall be made to any Holder of any of the Subordinated Notes on account thereof (except as provided
in the next sentence). Any payment or distribution, whether in cash, securities or other property (other than (x) securities of
the Company or any other corporation provided for by a plan of reorganization or readjustment the payment of which is subordinate,
at least to the extent provided in these subordination provisions with respect to the indebtedness evidenced by the Subordinated
Notes, to the payment of all Senior Indebtedness at the time outstanding and to any securities issued in respect thereof under
any such plan of reorganization or readjustment and (y) payments made from a defeasance trust created pursuant to Article Eleven
of the Indenture), which would otherwise (but for these subordination provisions) be payable or deliverable in respect of the Subordinated
Notes shall be paid or delivered directly to the holders of Senior Indebtedness in accordance with the priorities then existing
among such holders until all Senior Indebtedness (including any interest thereon accruing after the commencement of any such proceedings)
shall have been paid in full.

 

If an event of default (as defined in the
Indenture) with respect to Subordinated Notes of this series shall occur and be continuing, the principal of the Subordinated Notes
of this series may be declared due and payable in the manner and with the effect provided in the Indenture.

 

The Indenture contains provisions for defeasance
at any time of the entire indebtedness of this Subordinated Note upon compliance by the Company with certain conditions set forth
in Article Eleven thereof, which provisions apply to this Subordinated Note.

 

The Indenture contains provisions permitting
the Company and the Trustee, without the consent of the holders of Securities, to establish, among other things, the form and terms
of any series of Securities issuable thereunder by one or more supplemental indentures, and, with the consent of the holders of
not less than a majority of the principal amount of Securities at the time Outstanding which are affected thereby, to modify the
Indenture or any supplemental indenture or the rights of the holders of Securities of such series to be affected, provided that
no such modification shall, without the consent of the holder of each Outstanding Security so affected, (x) change the Stated Maturity
of the principal of, or any installment of principal of or interest on, any Security, or reduce the principal amount thereof or
the rate of interest thereon or any premium thereon, or change any place of payment where, or the coin or currency in which any
Security or any premium or interest thereon is payable, or impair the right to institute suit for the enforcement of any such payment
on or after the Stated Maturity thereof (or, in the case of redemption on or after the Redemption Date) or modify the provisions
of the Indenture with respect to the subordination of the Securities in a manner adverse to the Securityholders or (y) reduce the
aforesaid percentage in principal amount of the Outstanding Securities of any series, the consent of the holders of which is required
for any supplemental indenture, or the consent of whose holders is required for any waiver provided for in the Indenture, or (z)
modify certain other provisions of the Indenture, as set forth in Section 13.02 of the Indenture.

 

    	6

    	 

    

 

No reference herein to the Indenture and
no provision of this Subordinated Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of and interest on this Subordinated Note at the times, place and rate, and in the coin
or currency, herein prescribed.

 

As provided in the Indenture and subject
to certain limitations therein set forth, the transfer of definitive Subordinated Notes in certificated form is registrable in
the register maintained by the Company in The City of New York for such purpose, upon surrender of the definitive Subordinated
Note for registration of transfer at the office or agency of the registrar, duly endorsed by, or accompanied by a written instrument
of transfer in form satisfactory to the Company and the registrar duly executed by, the holder thereof or his attorney duly authorized
in writing, and thereupon one or more new Subordinated Notes of this series and of like tenor, of authorized denominations and
for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

No service charge shall be made for any
such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge payable in connection therewith.

 

Prior to due presentment of this Subordinated
Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in
whose name this Subordinated Note is registered as the owner hereof for all purposes, whether or not this Subordinated Note be
overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

The Company will pay additional amounts
("Additional Amounts") to the beneficial owner of any Subordinated Note that is a non-United States person in order to
ensure that every net payment on such Subordinated Note will not be less, due to payment of U.S. withholding tax, than the amount
then due and payable. For this purpose, a "net payment" on a Subordinated Note means a payment by the Company or a paying
agent, including payment of principal and interest, after deduction for any present or future tax, assessment or other governmental
charge of the United States. These Additional Amounts will constitute additional interest on the Subordinated Note.

 

The Company will not
be required to pay Additional Amounts, however, in any of the circumstances described in items (1) through (14) below.

 

		(1)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely
by reason of the beneficial owner:

 

    	7

    	 

    

 

		(a)	having a relationship with the United States as a citizen,
resident or otherwise;

		(b)	having had such a relationship in the past or

		(c)	being considered as having had such a relationship.

 

		(2)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely
by reason of the beneficial owner:

 

		(a)	being treated as present in or engaged in a trade or
business in the United States;

		(b)	being treated as having been present in or engaged in
a trade or business in the United States in the past or

		(c)	having or having had a permanent establishment in the
United States.

 

		(3)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld in
whole or in part by reason of the beneficial owner being or having been any of the following (as such terms are defined in the
Internal Revenue Code of 1986, as amended):

 

		(a)	personal holding company;

		(b)	foreign private foundation or other foreign tax-exempt
organization;

		(c)	passive foreign investment company;

		(d)	controlled foreign corporation or

		(e)	corporation which has accumulated earnings to avoid United
States federal income tax.

 

		(4)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely
by reason of the beneficial owner owning or having owned, actually or constructively, 10 percent or more of the total combined
voting power of all classes of stock of the Company entitled to vote or by reason of the beneficial owner being a bank that has
invested in a Subordinated Note as an extension of credit in the ordinary course of its trade or business.

 

For purposes of items (1) through
(4) above, "beneficial owner" means a fiduciary, settlor, beneficiary, member or shareholder of the holder if the holder
is an estate, trust, partnership, limited liability company, corporation or other entity, or a person holding a power over an estate
or trust administered by a fiduciary holder.

 

		(5)	Additional Amounts will not be payable to any beneficial
owner of a Subordinated Note that is a:

 

    	8

    	 

    

 

		(a)	fiduciary;

		(b)	partnership;

		(c)	limited liability company or

		(d)	other fiscally transparent entity

 

			or that is not the sole beneficial owner of the Subordinated Note, or any portion of the Subordinated
Note. However, this exception to the obligation to pay Additional Amounts will only apply to the extent that a beneficiary or settlor
in relation to the fiduciary, or a beneficial owner or member of the partnership, limited liability company or other fiscally transparent
entity, would not have been entitled to the payment of an Additional Amount had the beneficiary, settlor, beneficial owner or member
received directly its beneficial or distributive share of the payment.

 

		(6)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld solely
by reason of the failure of the beneficial owner or any other person to comply with applicable certification, identification,
documentation or other information reporting requirements. This exception to the obligation to pay Additional Amounts will only
apply if compliance with such reporting requirements is required by statute or regulation of the United States or by an applicable
income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental
charge.

 

		(7)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is collected or imposed by
any method other than by withholding from a payment on a Subordinated Note by the Company or a paying agent.

 

		(8)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld by
reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after
the payment becomes due or is duly provided for, whichever occurs later.

 

		(9)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is imposed or withheld by
reason of the presentation by the beneficial owner of a Subordinated Note for payment more than 30 days after the date on
which such payment becomes due or is duly provided for, whichever occurs later.

 

		(10)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any:

 

		(a)	estate tax;

		(b)	inheritance tax;

 

    	9

    	 

    

 

		(c)	gift tax;

		(d)	sales tax;

		(e)	excise tax;

		(f)	transfer tax;

		(g)	wealth tax;

		(h)	personal property tax or

		(i)	any similar tax, assessment, withholding, deduction or
other governmental charge.

 

		(11)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment, or other governmental charge required to be withheld by any
paying agent from a payment of principal or interest on a Subordinated Note if such payment can be made without such withholding
by any other paying agent.

 

		(12)	Additional amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any tax, assessment or other governmental charge that is required to be made pursuant
to any European Union directive on the taxation of savings income or any law implementing or complying with, or introduced to
conform to, any such directive.

 

		(13)	Additional amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any withholding, deduction, tax, duty assessment or other governmental charge that
would not have been imposed but for a failure by the holder or beneficial owner of a Subordinated Note (or any financial institution
through which the holder or beneficial owner holds the Subordinated Note or through which payment on the Subordinated Note is
made) to take any action (including entering into an agreement with the Internal Revenue Service, or a governmental authority
of another jurisdiction if the holder is entitled to the benefits of an intergovernmental agreement between that jurisdiction
and the United States) or to comply with any applicable certification, documentation, information or other reporting requirement
or agreement concerning accounts maintained by the holder or beneficial owner (or any such financial institution), or concerning
ownership of the holder or beneficial owner, or any substantially similar requirement or agreement.

 

		(14)	Additional Amounts will not be payable if a payment on
a Subordinated Note is reduced as a result of any combination of items (1) through (13) above.

 

Except as specifically
provided herein, the Company will not be required to make any payment of any tax, assessment or other governmental charge imposed
by any government or a political subdivision or taxing authority of such government.

 

As used in this Subordinated
Note, "United States person" means:

 

    	10

    	 

    

 

		(a)	any individual who is a citizen or resident of the United
States;

		(b)	any corporation, partnership or other entity created
or organized in or under the laws of the United States;

		(c)	any estate if the income of such estate falls within
the federal income tax jurisdiction of the United States regardless of the source of such income and

		(d)	any trust if a United States court is able to exercise
primary supervision over its administration and one or more United States persons have the authority to control all of the substantial
decisions of the trust.

 

Additionally, "non-United
States person" means a person who is not a United States person, and "United States" means the states of the United
States of America and the District of Columbia, but excluding its territories and its possessions.

 

Except as provided
below, the Subordinated Notes may not be redeemed prior to maturity.

 

		(1)	The Company may, at its option, redeem the Subordinated
Notes if:

 

		(a)	the Company becomes or will become obligated to pay Additional
Amounts as described above;

		(b)	the obligation to pay Additional Amounts arises as a
result of any change in the laws, regulations or rulings of the United States, or an official position regarding the application
or interpretation of such laws, regulations or rulings, which change is announced or becomes effective on or after September 10,
2013 and

		(c)	the Company determines, in its business judgment, that
the obligation to pay such Additional Amounts cannot be avoided by the use of reasonable measures available to it, other than
substituting the obligor under the Subordinated Notes or taking any action that would entail a material cost to the Company.

 

		(2)	The Company may also redeem the Subordinated Notes, at
its option, if:

 

		(a)	any act is taken by a taxing authority of the United
States on or after September 10, 2013, whether or not such act is taken in relation to the Company or any affiliate, that results
in a substantial probability that the Company will or may be required to pay Additional Amounts as described above;

		(b)	the Company determines, in its business judgment, that
the obligation to pay such Additional Amounts cannot be avoided by the use of reasonable measures available to it, other than
substituting the obligor under the Subordinated Notes or taking any action that would entail a material cost to the Company and

		(c)	the Company receives an opinion of independent counsel
to the effect that an act taken by a taxing authority of the United States results in a substantial probability that the Company
will or may be required to pay the Additional Amounts described above, and delivers to the Trustee a certificate, signed by a
duly authorized officer, stating that based on such opinion the Company is entitled to redeem the Subordinated Notes pursuant
to their terms.

 

    	11

    	 

    

 

Any redemption of the Subordinated Notes
as set forth in clauses (1) or (2) above shall be in whole, and not in part, and will be made at a redemption price equal to 100%
of the principal amount of the Subordinated Notes Outstanding plus accrued interest thereon to the date of redemption. Holders
shall be given not less than 30 days nor more than 60 days’ prior notice by the Trustee of the date fixed for such redemption.

 

All terms used in this Subordinated Note
which are defined in the Indenture shall have the meanings assigned to them in the Indenture. The Subordinated Notes are governed
by the laws of the State of New York.

 

    	12Exhibit 4.1

 

EMPLOYMENT AND NON-COMPETITION AGREEMENT

 

This Employment
Agreement (“Agreement”) dated February 22, 2011, effective as of an employment starting date to be decided
between the parties and that will occur not later than March 20, 2011 (“Effective Date”), by and between Can-Fite
Biopharma Ltd., an Israeli company with its principal offices in 10 Bareket Street, Petach Tikva, Israel, (the “Company”), and
Barak Singer (I.D. Number: 029092509), an individual whose address is 23 Yeshoron Street, Hod Hasharon, Israel (the “Employee”).

 

WITNESSETH:

 

WHEREAS, the Company
desires to employ Employee as its Vice President of Business Development (or any other title to be agreed upon between the Company
and the Employee), and Employee desires to be employed by the Company in such capacity, on the terms and conditions set forth below:

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual promises and covenants herein contained, the parties hereto agree as follows:

 

		1.	DEFINITIONS.

 

		1.1.	Capitalized terms shall have the meanings ascribed to them in this Agreement.

 

		2.	EMPLOYMENT; DUTIES.

 

		2.1.	The Company hereby employs Employee, and Employee hereby accepts employment, to serve in a position
of Vice President of Business Development (or any other title to be agreed upon between the Company and the Employee) on the terms
and conditions set forth below.

 

		2.2.	Employee shall have responsibility for performing such other services and duties as are normally
incident to the position held by Employee and are commensurate with Employee’s background, education and professional standing
and as are requested, from time to time, of Employee by the Company’s management. The Employee shall report to the Company’s CEO.

 

		2.3.	Unless otherwise agreed by the Company, Employee shall perform his duties hereunder at the Company’s
facilities in Israel, which are currently located at Petach Tikva, Israel. Employee hereby acknowledges that the Company may change
the location of its facilities to a new location, and agrees that, subject to applicable law, such change, in and of itself, will
not be deemed to have adversely changed Employee’s terms of employment hereunder, provided that the distance between the Company’s
present and new facilities will not exceed 60 kilometers.

 

    	 

    	 

    

 

		2.4.	Employee shall devote his or her entire business time, attention and efforts to the performance
of his or her duties and responsibilities under this Agreement and the business and affairs of the Company. Unless otherwise agreed
in writing by the Company, Employee shall not during the term of this Agreement be engaged (whether or not during normal business
hours) in any other business or professional activity whether or not such activity is pursued for gain, profit or other pecuniary
advantage.

 

		2.5.	The Employee shall be employed
                                                                by the Company on a full time basis. The Employee’s employment
                                                                with the Company is in accordance with the standard Company policy
                                                                regarding work days and organized holidays, which may be amended
                                                                at any time by the management of the Company, provided
                                                                such policy does not violate any applicable laws. The Company’s
                                                                policy, as of the date hereof, is to operate five (5) days a week
                                                                (Sunday to Thursday (inclusive)) and that all standard Jewish
                                                                holidays shall be regarded as organized holidays.

 

		2.6.	With regard to this Agreement and with regard to the Employee’s employment with the Company, no
other agreement; or provision from any other agreement; or custom, or customary practice which exists or which will come into existence
in the future between the Company and its employees, will be applicable to the employment relationship between the Company and
the Employee.

 

		3.	TERM.

 

Employee’s employment
with the Company shall commence on the Effective Date and, subject to Section 8 below, shall be for an indefinite period
of time; provided, however, that termination of the employment of the Employee shall be upon sixty days (60) days prior written
notice to the other party (the “Advance Notice”). In the event of termination of employment, the Employee,
if requested by the Company, shall continue to render his services, and shall be paid his regular compensation up to the date
of termination. Notwithstanding the aforesaid, the employment may be terminated for “cause” pursuant to Section 8 hereof
in which case employment shall cease immediately.

 

		4.	COMPENSATION AND BENEFITS

 

As compensation for the performance
of his duties on behalf of the Company, Employee shall be entitled to the compensation set forth in Schedule A attached
hereto. The “Salary” (as defined in Schedule A) and the other benefits payable to Employee hereunder shall be reviewed
on an annual basis, in accordance with the Company’s general practice.

 

The
Employee will also receive options according to the Company’s stock option plan and subject to the approval of the
Board of Directors, as detailed in Schedule A.

 

    	2

    	 

    

 

		5.	REPRESENTATIONS AND WARRANTIES BY EMPLOYEE

 

Employee hereby represents and
warrants to the Company as follows:

 

		5.1.	Neither the execution and delivery of this Agreement nor the performance by Employee of his or
her duties and other obligations hereunder violate or will violate any statute, law, determination or award, or conflict with or
constitute a default under (whether immediately, upon the giving of notice or lapse of time or both) any prior employment agreement,
contract, or other instrument to which Employee is a party or by which he or she is bound.

 

		5.2.	Employee has the full right, power and legal capacity to enter and deliver this Agreement and to
perform his or her duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of
Employee enforceable against him or her in accordance with its terms. No approvals or consents of any persons or entities are required
for Employee to execute and deliver this Agreement or perform his or her duties and other obligations hereunder.

 

		6.	NONDISCLOSURE AND COMPETITVE ACTIVITY

 

		6.1.	The terms of the undertaking attached hereto as Schedule B, which will be signed
and executed as of the date hereof shall be incorporated herein and constitute an integral part of this Agreement for any purpose.

 

		7.	REMEDIES.

 

		7.1.	If Employee breaches any or all of the covenants set forth in Schedule B attached hereto, the Company
will be entitled to file a claim with an Israeli court for the following remedies:

 

		7.1.1.	Damages from Employee;

 

		7.1.2.	In addition to its right to damages and any other rights it may have, to obtain injunctive or other
equitable relief to restrain any breach or threatened breach or otherwise to specifically enforce the provisions of Schedule B
attached hereto, it being agreed that money damages alone would be inadequate to compensate the Company and would be an inadequate
remedy for such breach.

 

		7.2.	The rights and remedies of the parties to this Agreement are cumulative and not alternative.

 

		8.	TERMINATION.

 

		8.1.	Employee’s employment hereunder
                                                                shall commence on the Effective Date, and shall continue for the
                                                                period set forth in Section 3 hereof unless sooner terminated
                                                                upon the first to occur of the following events:

 

    	3

    	 

    

 

		8.1.1.	The Employee has reached the “Retirement Age”, as such term is defined in the Equal Retirement
Age for the Employee Act - 1987, as shall be amended from time to time.

 

		8.1.2.	The death or disability of Employee
                                                                  (for purposes of this Section 8 “disability”
                                                                  shall be deemed to have occurred if Employee is unable, due
                                                                  to any physical or mental disease or condition, to perform his
                                                                  normal duties of employment for 120 days in any 12-month period).

 

		8.1.3.	The Company’s decision to cease the employment of the Employee, other than for “cause”,
subject to the Advance Notice period.

 

		8.1.4.	The Employee’s decision to cease hiss employment with the Company, subject to the Advance Notice
period.

 

		8.2.	Termination by the Company for just cause. Any of the following actions or omissions by
Employee shall constitute just cause:

 

		8.2.1.	Material breach by Employee of any of the covenants set forth in Schedule B attached hereto;

 

		8.2.2.	Material breach by Employee of any provision of this Agreement other than Schedule B attached hereto
which is not cured by Employee within fifteen (15) days after his receipt of notice thereof from the Company containing a description
of the breach or breaches alleged to have occurred;

 

		8.2.3.	Any act of moral turpitude by Employee or action by Employee to intentionally harm the Company.

 

		8.3.	Termination by Employee for just cause. Any of the following actions or omissions by the
Company shall constitute just cause:

 

		8.3.1.	Material breach by the Company of any provision of this Agreement which is not cured by the Company
within fifteen (15) days after its receipt of notice thereof from Employee containing a description of the breach or breaches alleged
to have occurred;

 

		8.3.2.	Any action by the Company to intentionally harm Employee.

 

		8.4.	Upon termination pursuant to Section
                                                                8.1 above, Employee (or his estate or guardian in the event
                                                                of termination pursuant to subsection 8.1.1 above) shall be entitled
                                                                to receive the Salary accrued but unpaid as of the date of termination,
                                                                and accrued vacation pay and all other payments required by law
                                                                and/or by this Agreement. The Company will be entitled to deduct
                                                                from the Employee Salary any amount owed by the Employee to the
                                                                Company, due to (a) any equipment and property belonging to the
                                                                Company and not returned by the Employee within fifteen (15) days
                                                                after his receipt of notice thereof from the Company containing
                                                                a description of such equipment or
                                                                property belonging to the Company, or (b) any other amount paid
                                                                to the Employee in excess of the Employee Salary.

 

    	4

    	 

    

 

		9.	NOTICES

 

All notices and other communications
required or permitted hereunder shall be in writing, shall be effective when given, and shall in any event be deemed to be given
upon receipt (a) five (5) days after deposit with the Postal Service, if delivered by mail, (b) upon delivery, if delivered by
hand, or (c) one (1) business day after the business day of facsimile transmission.

 

		10.	MISCELLANEOUS

 

All documents, exhibits and Schedules
attached to this Agreement constitute an integral part hereof. If any provision of this Agreement shall be declared by a court
of competent jurisdiction to be invalid, illegal or incapable of being enforced in whole or in part, the remaining conditions and
provisions or portions thereof shall nevertheless remain in full force and effect and enforceable, and no provision shall be deemed
dependent upon any other covenant or provision unless so expressed herein. This Agreement and all Schedules attached hereto contain
the entire agreement of the parties relating to the subject matter hereof, and the parties hereto have made no agreements, representations
or warranties relating to the subject matter of this Agreement which are not set forth herein. No modification of this Agreement
shall be valid unless made in writing and signed by the parties hereto. The rights, benefits, duties and obligations under this
Agreement shall inure to, and be binding upon, the Company, its successors assigns and any successor to the Company or to all or
substantially all of the Company’s business and/or assets, and upon Employee and his or her legal representatives, executors, administrators,
successors, heirs, distributees, devisees and legatees. This Agreement constitutes a personal service agreement, and the performance
of Employee’s obligations hereunder may not be transferred or assigned by Employee. The failure of either party to insist upon
the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment
of future compliance therewith or with any other term, condition or provision hereof, and said terms, conditions and provisions
shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be
effective for any purpose whatsoever unless such waiver is in writing and signed by such party. The headings of sections are inserted
for convenience and shall not affect any interpretation of this Agreement. This Agreement may be executed by any of the parties
hereto in counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one
and the same instrument.

 

		11.	GOVERNING LAW

 

This Agreement shall be governed
by, and construed and interpreted in accordance with, the laws of the State of Israel, and the sole and exclusive place of jurisdiction
in any matter arising out of or in connection with this Agreement shall be applicable courts in Tel-Aviv.

 

    	5

    	 

    

 

[The remainder of this page is left intentionally blank]

 

    	6

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as of the day and year first above written.

 

	 	 	Can-Fite Biopharma Ltd. (the “Company”)
	 	 	 	 
	Date:   22/2/2011	 	By:	/s/ Pnina Fishman
	 	 	Title:	Pnina Fishman, CEO
	 	 	 	 
	 	 	Employee
	 	 	 	 
	Date:   _______	 	 	 
		 	 	 
	 	 	/s/ Barak Singer
	 	 	Barak Singer

 

    	7

    	 

    

 

SCHEDULE A

 

COMPENSATION

 

		(a)	Monthly Salary.

The Company shall pay Employee
an aggregate monthly salary of Thirty Thousand New Israeli Shekels (NIS 30,000), (the the “Salary”). Accordingly,
the Salary shall be inclusive of all overtime and other similar compensation and shall be payable not later than the 10th day
of each month with respect to the preceding month, in accordance with the Company’s payroll practices. The Employee shall
be entitled to receive cost-of-living adjustments “Tosefet Yoker” or other statutory or mandatory required increase
in salary. The Company shall deduct from the salary all national insurance fees, health insurance fees, income tax and any other
amounts required by law, and shall provide the Employee with requisite documentation regarding such deductions.

 

The duties of the Employee in
accordance with this Agreement involve duties that require of him special personal care and loyalty, and therefore the directives
of the Work Hours and Rest Law, 1951, or any law to be enacted in its place, will not be applicable to the Employee or to his activities
which he will perform for the Company. The Employee will not be entitled to remuneration according to the Work Hours and Rest Law,
1951.

 

		(b)	Managers Insurance.

Within ten days after the end
of each month during the employment of Employee hereunder (or such other day as is consistent with the Company’s general
practices), the Company shall pay an aggregate amount equal to 18-1/3% of the Employee’s monthly Salary for the preceding
month to a Managers Insurance (Bituach Manahalim) policy (the “Policy”) and/or a comprehensive pension plan
(“Pension Plan”) through an agency and with an insurance company or a pension fund, to be selected
by the Employee, to be divided as follows: 8-1/3% towards Severance (the “Company’s Severance Contribution”);
5% toward provident (compensation). In addition the Company shall pay up to 2-1/2% of the Employee’s Salary towards
loss of (working capacity) disability insurance (depending on the cost to the Company necessary to provide coverage). Similarly,
at the beginning of each month the Company shall deduct from the Salary of Employee an amount equal to 5% of the Employee’s
monthly Salary for the preceding month, and shall pay such amount as premium payable in respect of the provident compensation
component of Policy. In the event the Employee elects to be insured under a Pension Plan, the allocations shall be modified in
accordance with the Pension Plans policies, provided, in any event they do not exceed the amounts set forth above.

 

		(c)	Section 14 of the Severance Compensation Law – 1963.

		(i)	It is hereby agreed that upon termination of employment under this Agreement, the Company shall
release to the Employee all amounts accrued in the Managers Insurance on account of both the Company’s and Employee’s contributions.
It is hereby clearly agreed and understood that the amounts accrued in the Managers Insurance on account the Company’s contribution
[i.e. 13.33% of each monthly Salary payment] shall be in lieu and in full and final substation of any severance pay the Employee
shall be or become entitled to under any applicable Israeli law.

 

    	8

    	 

    

 

		(ii)	The Company hereby waives in advance
                                                                any right to any amounts accrued in the Managers Insurance, unless
                                                                the Employee is either not entitled to Severance Pay according
                                                                to Section 17 of the Severance Compensation Act, 1963, or has
                                                                withdrawn amounts from the Managers Insurance not due or
                                                                as a result of an “Entitling Event”, as such term
                                                                is defined in the General Approval of the Labor Minister, dated
                                                                June 30, 1998, issued in accordance to the said Section 14 (the
                                                                “General Approval”), in which case the Company
                                                                may have the right to deny the employee only the amounts attributed
                                                                to the Company’s Severance Contribution accrued in the Managers
                                                                Insurance.

 

		(iii)	Sub-Sections (i) and (ii) are in accordance with Section 14 of the Severance
Compensation Act, 1963 and the General Approval, a copy of which is attached hereby to this Schedule A as Exhibit A.

 

		(d)	Study Fund (Keren Hishtalmut).

At the end of each month, during
the employment of the Employee hereunder (or such other day as is consistent with the Company’s general practices), the Company
shall pay an amount equal to up to 7-1/2% of the Employee’s monthly Salary for the preceding month (the “Maximum Amount”),
and if such amount exceeds the amount which is qualified for tax purposes for the Employee, the Employee shall bear the tax above
the approved qualified tax (the “Tax Amount”), to a Study Fund (Keren Hishtalmut) designated by the Employee
(the “Fund”), and shall deduct from the Salary of the Employee an amount equal to up to 2-1/2% of the Employee’s
monthly Salary for the preceding month and pay the same to the Fund. Any amounts resulting from the Maximum Amount less the Tax
Amount, shall be paid to the Employee after deduction at source of any applicable taxes, payable on the date stated in Section
(a) above.

 

		(e)	Vacation/Sick Leave/Vacation allowance (Recuperation Pay).

The Employee shall be entitled
to Twenty (20) working days of paid vacation annually during the term of this Agreement (prorated for any calendar year during
which he is employed hereunder). The Employee may carry forward the unused portion of such vacation for a period of two years only,
provided, however, that he use at least 4 days of that portion each year. The value of any unused vacation shall be paid to the
Employee, pro rata, on the basis of the Salary, at the end of the month during which such excess vacation time may be accrued.
Nothing in this Section may derogate from the Employee’s rights and benefits by applicable law.

 

The Employee
will be entitled to eighteen (18) days of fully paid sick leave per year. The Employee may carry forward any unused sick leave,
not to exceed the maximum prescribed by law. The Company is entitled to offset any sick leave payment against any monies received
by the Employee due to his loss of working capacity insurance.

 

The Employee will be entitled
to receive annual payment for Recuperation Days (Dmei Havraa’) at the rate defined by law from time to time for each Recuperation
Day.

 

    	9

    	 

    

 

		(f)	Company Automobile.

While the Employee is actively
employed by the Company, the Company will lease an automobile from a leasing Company, chosen at the Company’s sole discretion,
and in the same level as automobiles leased by the senior executives of the Company, and will place such automobile at the disposal
of the Employee under the terms of the Company’s general leasing plan (to be provided to the Employee upon provision of
the automobile). The make, size and design of the automobile will be subject to the Company’s sole discretion. The Employee
shall abide by all traffic laws and regulations, drive cautiously and care for the proper maintenance of the car. The Company
shall bear all of the fixed and variable maintenance costs and actual expenses incurred directly in connection with his use of
such automobile, including licenses, insurance, gas, repairs, parking at the Company offices, etc. but excluding any fines. The
Employee will be compensated for all taxes he will be liable to as a consequence of the benefits of Employee under this Section
(“Gilum”).

 

		(g)	Out of Pocket Expenses.

The Company
shall pay or reimburse the Employee for all normal, usual and necessary expenses incurred or paid by the Employee in the performance
of his duties hereunder, against receipt by the Company of appropriate vouchers, receipts or other proof of the Employee’s expenditures,
all subject to guidelines regarding such expenses which shall be approved by Board of Directors from time to time.

 

		(h)	Mobile Phone. The Company shall provide the Employee with the use of a company mobile phone
in such a model as is normally granted to employees of the same position as the Employee (the “Company Mobile Phone”).
The Company shall bear all costs of the Company Mobile Phone, including insurance, repairs, related maintenance, phone use and
shall also bear the applicable tax liability for the grant of use of the Company Mobile Phone. Immediately upon termination of
this Agreement for whatever reason, the Employee will return the Company Mobile Phone to the Company.

 

    	10

    	 

    

 

 

    	11

    	 

    

 

THIS UNDERTAKING
(the “Undertaking”), is entered into as of the ___ day of February, 2011, by Barak Singer, ID No. 029092509,
an individual residing at 23 Yeshoron Street, Hod Hasharon, Israel (the “Employee”)

 

WHEREAS the
Employee has entered or intends to enter an Employment Agreement (the “Employment Agreement”), with Can-Fite
Biopharma Ltd., an Israeli company (the “Company”); and

 

WHEREAS the Employee agreed to enter
into this Undertaking

 

NOW, THEREFORE,
the Employee undertakes and warrants towards the Company and any subsidiary and parent company of the Company as follows:

 

		1.	ACKNOWLEDGMENT

 

Employee acknowledges that (a)
he occupies a position of trust and confidence with the Company and shall continue to occupy such position of trust and confidence
with the Company, and has or shall become familiar with the following, any and all of which constitute confidential information
of the Company, (collectively, the “Confidential Information”): (i) any and all trade secrets concerning the business
and affairs of the Company, product specifications, data, know-how, formulae, compositions, processes, designs, sketches, photographs,
graphs, drawings, samples, inventions and ideas, past, current and planned research and development, current and planned manufacturing
and distribution methods and processes, customer lists, current and anticipated customer requirements, price lists, market studies,
business plans, computer software and programs (including object code and source code), computer software and database technologies,
systems, structures and architectures (and related processes, formulae, compositions, improvements, devices, know-how, inventions,
discoveries, concepts, ideas, designs, methods and information), of the Company and any other information, however documented,
of the Company that is a trade secret within the meaning of applicable law; (ii) any and all information concerning the business
and affairs of the Company (which includes historical financial statements, financial projections and budgets, historical and projected
sales, capital spending budgets and plans, the names and backgrounds of key personnel, personnel training and techniques and materials),
however documented; and (iii) any and all notes, analysis, compilations, studies, summaries, and other material prepared by or
for the Company containing or based, in whole or in part, on any information included in the foregoing; (b) the business
of the Company is international in scope; (c) the products and services of the Company are or shall be marketed throughout
the world; (d) the Company competes with or shall compete with other businesses that are or could be located in any part
of the world; (e) the provisions of this Undertaking are reasonable and necessary to protect and preserve the Company’s
business, and (f) the Company would be irreparably damaged if Employee were to breach the covenants set forth in Sections
2,3, and 4 of this Undertaking. For purposes of this Undertaking, Confidential Information does not include any of the foregoing
items which have become publicly known and made generally available through no wrongful act of Employee or of others who were under
confidentiality obligations as to item or items involved

 

    	12

    	 

    

 

		2.	CONFIDENTIAL INFORMATION

 

		2.1	Employee agrees at all times during the term of his employment and thereafter, to hold in strictest
confidence, and not to use, except for the benefit of the Company or to disclose to any person, firm or corporation without written
authorization of the Board of Directors of the Company, any Confidential Information of the Company. Employee shall not: (i) use
any such information, directly or indirectly, for himself or herself or others; and (ii) take any such material or reproductions
thereof from the Company’s facilities at any time during his or her employment by the Company except as required in connection
with Employee’s duties to the Company. Employee agrees to return all such material and reproductions thereof (whether or not merged
with other works) in his or her possession to the Company, promptly upon request and in any event immediately upon termination
of employment.

 

		2.2	Except with prior written authorization by the Company, Employee agrees not to disclose or publish
any of the Confidential Information or material of the Company, its clients, partners, shareholders or suppliers, or any other
party to whom the Company owes an obligation of confidence, at any time during or after his or her employment with the Company.

 

		2.3	The Employee further agrees that unless the Employee first obtains the prior written approval of
the Company or any of it’s authorized representatives, he or she shall neither issue, produce, publish, put out, print, distribute
or circulate any article, abstract, commentary, critique or any other kind of publication, nor shall he or she deliver any lecture,
either for consideration or without, which includes Confidential Information, material or any other proprietary information or
trade secrets of the Company.

 

		2.4	Employee agrees, during his or her employment with the Company, not to improperly use or disclose
any proprietary information or trade secrets of any former or concurrent employer or other person or entity and that he or she
will not bring onto the premises of the Company any unpublished document or proprietary information belonging to any such employer,
person or entity unless consented to in writing by such employer, person or entity.

 

		2.5	Employee recognizes that the Company has received and in the future will receive from third parties
their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information
and to use it only for certain limited purposes. Employee agrees to hold all such confidential or proprietary information in the
strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying out
such Employee’s work for the Company consistent with the Company’s agreement with such third party.

 

    	13

    	 

    

 

		3.	INVENTIONS.

 

		3.1	Employee has attached hereto, as
                                                               Exhibit A, a list describing all inventions, original works
                                                               of authorship, developments, improvements, and trade secrets which
                                                               were made by Employee prior to his or her employment with the Company
                                                               (collectively referred to as “Prior Inventions”),
                                                               which belong to Employee, which relate to the Company’s proposed
                                                               business, products or research and development, and which are not
                                                               assigned to the Company hereunder; or, if no such list is attached,
                                                               Employee represents that there are no such Prior Inventions. If
                                                               in the course of his or her employment with the Company, Employee
                                                               incorporates into a product, process or machine of the Company
                                                               a Prior Invention owned by Employee or in which Employee has an
                                                               interest, the Company is hereby granted and shall have a nonexclusive,
                                                               royalty-free, irrevocable, perpetual, worldwide license to make,
                                                               have made, modify, use and sell such Prior Invention as part of
                                                               or in connection with such product, process or machine

 

		3.2	The Employee will disclose and deliver to the Company for the exclusive use and benefit of the
Company any Inventions (which in this paragraph shall mean any discovery, technique, design, formula, method of manufacture, inventions,
secret process, improvements, and modifications (whether or not capable of protection by rights in the nature of intellectual property))
which the Employee alone or with one or more others has made or discovered during the Term of Employment and which pertain to or
result from any work which the Employee has done or may hereafter do for the Company, promptly upon the making, devising, or discovering
of the same, and will give all information and data in his possession as to the exact mode of working, producing, and using the
same and also all such explanations and instructions as may in the view of the Company be necessary to enable the full and effectual
working, production, or use of the same and will at the expense of the Company furnish it with all necessary plans, drawings, formulae,
and models.

 

		3.3	The Employee will without charge to but at the expense of the Company execute and do all acts,
matters, documents, and things to enable the Company or its nominee to apply for and obtain protection for the Inventions in any
or all countries and to vest title in the Company or such nominee absolutely.

 

		3.4	The Employee hereby irrevocably appoints the Company to be his attorney in his name and on his
behalf to execute and do such acts, matters, documents, and things as aforesaid and generally to use his name for the purpose of
giving to the Company (or its nominee) the full benefit of the provisions of this section. In favor of any third party a certificate
signed by any director or the secretary of the Company that an instrument or act falls within the authority hereby conferred shall
be conclusive evidence that such is the case.

 

		3.5	During the Term of Employment and at all times thereafter the Employee will (whether by omission
or commission) do nothing to affect or imperil the validity of the protection for the Inventions obtained or applied for by the
Company or its nominee pursuant to this paragraph. The Employee will at the direction and expense of the Company render all assistance
within his or her power to obtain and maintain such protection or application or any extension thereof.

 

    	14

    	 

    

 

		3.6	Nothing in this Undertaking shall oblige the Company to seek patent or other protection for any
Invention nor to exploit any Invention.

 

		3.7	The Employee shall promptly disclose to the Company all copyright works or designs originated,
conceived, written, or made by him or her alone or with others (except only those works originated, conceived, written, or made
by him or her prior to being employed by the Company) and shall until such rights shall be fully and absolutely vested in the Company
hold them in trust for the Company.

 

		3.8	The Employee hereby assigns to the Company by way of future assignment all copyright, design right,
and other proprietary rights, if any, for the full terms thereof throughout the world in respect of all copyright works and designs
originated, conceived, written, or made by the Employee (except only those works or designs originated, conceived, written, or
made by the Employee wholly outside his or her normal working hours and wholly unconnected with his or her being employed by the
Company) during the period of his or her employment hereunder and during all previous periods of employment with the Company.

 

		3.9	The Employee will at the request and expense of the Company do all things
necessary or desirable to substantiate the rights of the Company under Section
4.8, and it is hereby acknowledged and agreed that the provisions of this paragraph shall survive
any termination of the Employment.

 

		3.10	For the removal of any doubt, it is hereby clarified that the provisions contained in Sections
4.2 and 4.8 above will apply also to any “Service Inventions” as defined in the Israeli Patent Law, 1967 (the “Patent
Law”). However, in no event will such Service Invention become the property of the Employee and the provisions contained
in Section 132(b) of the Patent Law shall not apply unless the Company provides in writing otherwise. The Employee will not be
entitled to royalties or other payment with regard to any Prior Inventions, Service Inventions or any of the intellectual property
rights set forth above, including any commercialization of such Prior Inventions, Service Inventions or other intellectual property
rights.

 

		4.	GENERAL

 

		4.1	The Employee acknowledges that the provisions of this Undertaking serve as an integral part of
the terms of his employment and reflect the reasonable requirements of the Company in order to protect its legitimate interests
with respect to the subject matter hereof. If any provision of this Undertaking (including any sentence, clause or part thereof)
shall be adjudicated to be invalid or unenforceable, such provisions shall be deemed amended to delete therefrom the portion thus
adjudicated to be invalid or unenforceable, such deletion to apply only with respect to the operation of such provision in the
particular jurisdiction in which such adjudicate is made. In addition, if any particular provision contained in this undertaking
shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed
by limiting and reducing such provision as to such characteristic so that the provision is enforceable o the fullest extent compatible
with applicable law as it shall then appear.

 

    	15

    	 

    

 

		4.2	The provisions of this Undertaking shall remain in full force and effect also following the termination
of the employment relationship between the Company and the Employee for whatever reason. This Undertaking shall not serve in any
manner as to derogate from any of the Employee’s obligations and liabilities under any applicable law.

 

	Signature:	/s/ Barak Singer	 
	 	Barak Singer	 

 

    	16

    	 

    

 

Exhibit A

 

LIST OF PRIOR INVENTIONS

AND ORIGINAL WORKS OF AUTHORSHIP

 

	Title	 	Date	 	Identifying Number
		 		 	or Brief Description
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

___X__ No inventions or improvements

 

_____ Additional Sheets Attached

 

	Signature of Employee:	/s/ Barak Singer	 

 

Print Name of Employee: Barak Singer

 

Date: 22/2/2011

 

    	17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]